Medicine and Dentistry
Systematic Review
100%
Patient with Cystic Fibrosis
100%
Cost-Effectiveness Analysis
100%
Ivacaftor
100%
Health Care Cost
31%
Randomized Controlled Trial
31%
Cystic Fibrosis
25%
Lifespan
18%
Forced Expiratory Volume
18%
Lung
18%
Placebo
18%
Quality of Life
12%
Adverse Event
6%
Aspartic Acid
6%
Meta-Analysis
6%
Lung Injury
6%
Lung Transplantation
6%
Quality Adjusted Life Year
6%
Sweat
6%
Health Technology
6%
Technology Assessment
6%
Open-Label Trial
6%
Protein Defect
6%
Treatment Effect
6%
Exon
6%
Nursing and Health Professions
Cost Effectiveness Analysis
100%
Systematic Review
100%
Patient with Cystic Fibrosis
100%
Ivacaftor
100%
Cystic Fibrosis
25%
Placebo
18%
Forced Expiratory Volume
18%
Quality of Life
12%
Clinical Effectiveness
12%
Confidence Interval
12%
Meta Analysis
6%
Quality Adjusted Life Year
6%
Biomedical Technology Assessment
6%
Incremental Cost-Effectiveness Ratio
6%
Adverse Event
6%
Lung Transplantation
6%
Open-Label Trial
6%
Lung Injury
6%
Aspartic Acid
6%
Protein Defect
6%
Psychology
Quality of Life
100%
Systematic Review
100%
Meta-Analysis
50%
Technology Assessment
50%
Biochemistry, Genetics and Molecular Biology
Cystic Fibrosis
100%
Ivacaftor
100%
Randomized Controlled Trial
31%
Lifespan
18%
Forced Expiratory Volume
18%
Exon
6%
Quality Adjusted Life Year
6%
Aspartic Acid
6%
Pharmacology, Toxicology and Pharmaceutical Science
Cystic Fibrosis
100%
Ivacaftor
100%
Randomized Controlled Trial
31%
Placebo
18%
Adverse Event
6%
Aspartic Acid
6%
Open-Label Trial
6%
Lung Injury
6%
Protein Defect
6%